INTRODUCTION AND AIM: @entity2675 ( @entity2675 ) is a @entity395 which represents only about 0.2% of all @entity5 . The ratio of female to @entity2675 is approximately 100:1. In this study, we review our experience with diagnosis, surgical treatment, and overall management of @entity1 with @entity2675 . METHODS: Overall, 5384 @entity0 @entity1 underwent surgery in Masaryk Memorial Cancer Institute, Brno, Czech Republic during the period of 2001 to 2009. Among these, seventeen were @entity1 . In these @entity1 , data on incidence, clinical symptoms, diagnostic procedures, types of surgical resection, histopathology, adjuvant systematic therapy, genetic investigation and therapeutic results were retrospectively reviewed from their medical records. RESULTS: None of the @entity1 have distant metastases at the time of surgery. In sixteen cases an invasive @entity5 was histopathologically diagnosed, one @entity1 had @entity3821 ( @entity3821 ). Eight @entity1 exhibited locally advanced stage of the disease (IIIB). All @entity1 were primarily treated surgically; in no case neoadjuvant therapy was recommended. From the five @entity1 operated primarily elsewhere, four underwent completion of modified radical mastectomy (RAME) at our institution and one @entity1 underwent subcutaneous (nipple-sparing) mastectomy without the surgery on lymph nodes. Twelve @entity1 were primarily diagnosed and operated at our institution. Ten of these were scheduled for RAME, one @entity1 was recommended total mastectomy with sentinel lymph node biopsy, and one @entity1 underwent total mastectomy without surgery on regional lymph nodes. Adjuvant therapy overall comprised radiotherapy, chemotherapy, hormonal therapy, and biological therapy. Investigation of BRCA genes was suggested in nine @entity1 , but the results of only four of them are available to date. Two @entity1 exhibited a mutation in BRCA genes. One mutation is explicitly pathogenic; another case represents variation with unknown clinical effect. Twelve @entity1 of the cohort are in complete remission, two are alive with distant metastases and three died (two on @entity5 , one on @entity65 ). CONCLUSION: Our study should point out a rare form of @entity0 . There are some particular differences between male and female @entity0 though the overall clinical management of both is generally similar. There is a necessity of appropriate health education to prevent late diagnosis of @entity0 in @entity1 . Genetic testing should be recommended to every male @entity1 with this disease.

[ XXXX --our experience].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men'] @entity3821 :: ('MESH:D002285', 'Disease') :: ['ductal carcinoma in situ', 'DCIS'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'mammary tumors--male breast cancer'] @entity2675 :: ('MESH:D018567', 'Disease') :: ['Male breast cancer', 'MBC', 'male breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer'] @entity395 :: ('MESH:D035583', 'Disease') :: ['rare disease'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity2675 :: (MESH:D018567,Disease) :: ['Male breast cancer']
